• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    9/1/23 1:31:10 PM ET
    $ACER
    $ADTX
    $AHG
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACER alert in real time by email

    Gainers

    • Axcella Health (NASDAQ:AXLA) stock increased by 68.6% to $0.39 during Friday's regular session. Axcella Health's stock is trading at a volume of 123.9 million shares as of 13:30 EST. This is 1539.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $28.7 million.
    • Trxade Health (NASDAQ:MEDS) stock increased by 40.18% to $10.71. Trxade Health's stock is trading at a volume of 11.9 million shares as of 13:30 EST. This is 1828.4% of its average full-day volume over the last 100 days. The company's market cap stands at $13.3 million.
    • Novo Integrated Sciences (NASDAQ:NVOS) shares rose 37.49% to $0.19. As of 13:30 EST, Novo Integrated Sciences's stock is trading at a volume of 148.8 million, which is 600.5% of its average full-day volume over the last 100 days. The company's market cap stands at $30.3 million.
    • Tivic Health Systems (NASDAQ:TIVC) shares moved upwards by 27.15% to $3.09. As of 13:30 EST, Tivic Health Systems's stock is trading at a volume of 1.8 million, which is 220.8% of its average full-day volume over the last 100 days. The company's market cap stands at $4.5 million.
    • LogicMark (NASDAQ:LGMK) stock increased by 26.25% to $2.5. Trading volume for LogicMark's stock is 1.9 million as of 13:30 EST. This is 4248.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.3 million.
    • SCWorx (NASDAQ:WORX) shares moved upwards by 24.94% to $0.23. As of 13:30 EST, this security is trading at a volume of 2.9 million shares, making up 53.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.7 million.

    Losers

    • Aditxt (NASDAQ:ADTX) shares decreased by 23.7% to $41.99 during Friday's regular session. As of 13:30 EST, Aditxt's stock is trading at a volume of 1.1 million, which is 1021.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $7.9 million.
    • Biodexa Pharmaceuticals (NASDAQ:BDRX) stock fell 22.72% to $6.17. As of 13:30 EST, this security is trading at a volume of 1.0 million shares, making up 169.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.4 million.
    • Akso Health Group (NASDAQ:AHG) shares decreased by 20.11% to $0.73. Trading volume for Akso Health Group's stock is 597.2K as of 13:30 EST. This is 483.7% of its average full-day volume over the last 100 days. The company's market cap stands at $16.8 million.
    • Catalyst Biosciences (NASDAQ:CBIO) shares fell 20.03% to $0.45. The current volume of 1.0 million shares is 147.2% of Catalyst Biosciences's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $16.9 million.
    • Acer Therapeutics (NASDAQ:ACER) stock decreased by 16.41% to $1.07. Trading volume for this security as of 13:30 EST is 3.9 million, which is 180.0% of its average full-day volume over the last 100 days. The company's market cap stands at $26.1 million.
    • Allarity Therapeutics (NASDAQ:ALLR) stock declined by 11.63% to $1.64. The current volume of 552.9K shares is 74.7% of Allarity Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $4.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACER alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACER
    $ADTX
    $AHG
    $ALLR

    CompanyDatePrice TargetRatingAnalyst
    Crescent Biopharma Inc.
    $CBIO
    1/28/2026$35.00Overweight
    Piper Sandler
    Crescent Biopharma Inc.
    $CBIO
    1/21/2026$35.00Buy
    Guggenheim
    Crescent Biopharma Inc.
    $CBIO
    8/25/2025$26.00Buy
    Jefferies
    Crescent Biopharma Inc.
    $CBIO
    8/11/2025$25.00Buy
    H.C. Wainwright
    Allarity Therapeutics Inc.
    $ALLR
    7/28/2025$9.00Buy
    Ascendiant Capital Markets
    Crescent Biopharma Inc.
    $CBIO
    7/14/2025$27.00Outperform
    Wedbush
    Crescent Biopharma Inc.
    $CBIO
    6/25/2025$28.00Buy
    Stifel
    Biodexa Pharmaceuticals plc American Depositary Shs
    $BDRX
    2/8/2024$8.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $ACER
    $ADTX
    $AHG
    $ALLR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients

    March 9, 2026 Biodexa Announces Support for Life's a Polyp FoundationFirst U.S. Patient Advocacy Group for FAP Patients Cardiff, UK – March 9, 2026 – Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, is pleased to recognise Life's a Polyp Foundation on its official launch following an initial financial grant from Biodexa to support the organization's vital work empowering patients with Familial Adenomatous Polyposis (FAP). The Life's a Polyp Foundation, led by dedicated FAP advocate Jenny Jones, marks the first U.S.-based patient advocacy group dedicated

    3/9/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crescent Biopharma Announces Grants of Inducement Awards

    WALTHAM, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 45,675 shares of the Company's ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the "Inducement Plan"). The options were approved on March 5, 2026 and were material to each employee's acceptanc

    3/6/26 4:15:00 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

             Extends Company Cash Runway into Mid-2028Financing Expected to Fund Completion of Phase 2 Ovarian Cancer TrialFinancing Supports Acceleration Toward Pivotal Trial and CommercializationFinancing Structured as Non-Convertible Debt Financing TARPON SPRINGS, Fla., March 6, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that it has closed a $20 million non-convertible debt financing with Streeterville Capital. The transaction is structured as a note purchase agreement pursuant to which the Com

    3/6/26 8:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACER
    $ADTX
    $AHG
    $ALLR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for OLPRUVA issued to ACER THERAPEUTICS INC

    Submission status for ACER THERAPEUTICS INC's drug OLPRUVA (ORIG-1) with active ingredient SODIUM PHENYLBUTYRATE has changed to 'Approval' on 12/22/2022. Application Category: NDA, Application Number: 214860, Application Classification: Type 5 - New Formulation or New Manufacturer

    12/23/22 1:58:04 PM ET
    $ACER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACER
    $ADTX
    $AHG
    $ALLR
    SEC Filings

    View All

    Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)

    3/9/26 9:02:24 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allarity Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)

    3/6/26 8:22:50 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aditxt Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Aditxt, Inc. (0001726711) (Filer)

    3/5/26 8:30:35 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACER
    $ADTX
    $AHG
    $ALLR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fairmount Funds Management Llc bought $18,237,600 worth of Ordinary Shares (1,360,000 units at $13.41) (SEC Form 4)

    4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)

    12/8/25 4:30:15 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Large owner Winvest Investment Fund Management Corp. bought $114,112 worth of shares (1,257,257 units at $0.09), increasing direct ownership by 34% to 4,074,587 units (SEC Form 4)

    4/A - LogicMark, Inc. (0001566826) (Issuer)

    11/12/24 3:46:00 PM ET
    $LGMK
    Industrial Specialties
    Health Care

    Large owner Winvest Investment Fund Management Corp. bought $306,880 worth of shares (3,464,987 units at $0.09), increasing direct ownership by 331% to 4,074,587 units (SEC Form 4)

    4 - LogicMark, Inc. (0001566826) (Issuer)

    10/18/24 9:31:15 PM ET
    $LGMK
    Industrial Specialties
    Health Care

    $ACER
    $ADTX
    $AHG
    $ALLR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Crescent Biopharma with a new price target

    Piper Sandler initiated coverage of Crescent Biopharma with a rating of Overweight and set a new price target of $35.00

    1/28/26 7:10:21 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Crescent Biopharma with a new price target

    Guggenheim initiated coverage of Crescent Biopharma with a rating of Buy and set a new price target of $35.00

    1/21/26 8:54:45 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Crescent Biopharma with a new price target

    Jefferies initiated coverage of Crescent Biopharma with a rating of Buy and set a new price target of $26.00

    8/25/25 8:12:09 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACER
    $ADTX
    $AHG
    $ALLR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Handley Michael K converted options into 8,824 shares (SEC Form 4)

    4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

    2/20/26 4:19:42 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Schneider Carine

    4 - LogicMark, Inc. (0001566826) (Issuer)

    2/5/26 4:35:54 PM ET
    $LGMK
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Director Pettitt John P

    4 - LogicMark, Inc. (0001566826) (Issuer)

    2/5/26 4:35:10 PM ET
    $LGMK
    Industrial Specialties
    Health Care

    $ACER
    $ADTX
    $AHG
    $ALLR
    Leadership Updates

    Live Leadership Updates

    View All

    Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

    January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is delighted to announce the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary along with her election to the Board of Directors of the Company with immediate effect. Ms Sharp is a senior finance professional having joined the Company as Group Financial Controller in December 2019. During her tenure, she has consistentl

    1/5/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that CEO, Jennifer Ernst, will participate in the eighth annual Constellation Forum, a global conversation on Bioelectronic Medicine. She will join other leaders in the field to discuss the opportunities for advancing bioelectronic medicine. When: Thursday, Oct. 23, at 11:55 a.m. ET/8:55 a.m. PT Panel Title: Building a Big Tent Bioelectronic Medicine stands to disrupt how we diagnose, treat, and manage disease, but fulfilling that promise requires broad alignment across the healthcare ecosystem. This session will explore how to rally the global community,

    10/22/25 2:00:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Interim results for the six months ended June 30, 2025

    September 12, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces its unaudited interim results for the six months ended June 30, 2025 which will also be made available on the Company's website at www.biodexapharma.com. OPERATIONAL HIGHLIGHTS The Company announced the following in the six months ended June 30, 2025: Allowance by the US Patent and Trademark Office of patent application No. 17/391-495 "Oral Rapamycin Nanopart

    9/12/25 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACER
    $ADTX
    $AHG
    $ALLR
    Financials

    Live finance-specific insights

    View All

    Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

         Received FDA Fast Track designation for stenoparib in advanced ovarian cancer Reported landmark median overall survival now exceeding 25 months in ongoing Phase 2 trialAdvanced DRP® platform through new licensing agreement TARPON SPRINGS, Fla., November 14, 2025 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provided an update on operational highlights for the third quarter ended September 30, 2025. "The third quarter of 2025 was another milestone period for Allarity as we ac

    11/14/25 9:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tivic Health to Report Third Quarter 2025 Financial Results on November 14th Via Conference Call and Webcast

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that it will report its third quarter results for 2025 via pre-recorded conference call and webcast on Friday, November 14, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 230582 Webcast Link https://www.webcaster5.com/Webcast/Page/2865/53145 About Tivic Health Systems, Inc. Tivic's dual platform utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell

    11/6/25 9:30:00 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

        - Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial - Expanded global IP protection by securing Australian patent acceptance for the stenoparib DRP® companion diagnostic- Secured new service contract with EU biotech for Allarity Medical Laboratory TARPON SPRINGS, Fla., August 15, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provided an update on operational highlights for the second quarter ended June 30, 2025. "The second quarter of 2025 marked a period

    8/15/25 4:30:00 PM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACER
    $ADTX
    $AHG
    $ALLR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    12/5/24 7:17:43 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by LogicMark Inc.

    SC 13D/A - LogicMark, Inc. (0001566826) (Subject)

    12/3/24 3:35:39 PM ET
    $LGMK
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    11/26/24 5:02:01 PM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary